Relationship Between Macular Thickness Measurement and Signal Strength in Optical Coherence Tomography
1 other identifier
observational
40
1 country
1
Brief Summary
Signal strength is a parameter introduced in analysis software version 4.0.1, of the OCT stratus, that combines SNR and uniformity of the signal within a scan The scale of signal strength ranges from 1 to 10, with 1 representing poor image quality and 10 representing excellent image quality It has been showed that signal strength has a better image quality discriminating ability than SNR The operation manual recommends a minimum signal strength of 5 for macular thickness measurement There is no consensus on the level of signal strength above which should be considered to be good quality The inclusion Criteria for acceptable signal strength varies widely in the literature the purpose of our study is to examine the relationship between signal strength and macular thickness measured by stratus OCT
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started May 2010
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2010
CompletedFirst Submitted
Initial submission to the registry
May 2, 2010
CompletedFirst Posted
Study publicly available on registry
May 4, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2013
CompletedSeptember 27, 2016
January 1, 2010
3 years
May 2, 2010
September 26, 2016
Conditions
Keywords
Eligibility Criteria
healthy
You may qualify if:
- healthy subjects in this study other than refractive error, all included eyes had no concurrent ocular pathologic features BCVA of at least 20/30, and had spherical refractive error within the range of
- D to 4.00 D
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Meir medical center
Kfar Saba, Israel
Study Officials
- PRINCIPAL INVESTIGATOR
Ori Segal, M.D
Sackler school of medicine Tel-Aviv university
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 2, 2010
First Posted
May 4, 2010
Study Start
May 1, 2010
Primary Completion
May 1, 2013
Study Completion
May 1, 2013
Last Updated
September 27, 2016
Record last verified: 2010-01